Latin America Parkinson’s Disease Treatment Market

 Latin America Parkinson’s Disease Treatment Market size ( 2024 to 2029)

The size of the Latin America Parkinson’s Disease Treatment Market was worth USD 0.60 billion in 2024 and is estimated to be growing at a CAGR of 5.98%, to reach USD 0.81 billion by 2029.

The increasing prevalence of Parkinson's disease (PD) and the rapid growth in the geriatric population with long expectancy, which is more susceptible to neurodegenerative diseases, are the key factors for developing the Latin American Parkinson’s disease treatment market. In addition, the growing awareness of the available treatment alternatives is also driving the market's growth. Parkinson's disease is more common in men than in women, according to the Parkinson Foundation. A higher incidence was found in men with an approximately 1.55 times higher risk than women. People over the age of 60 are mostly affected by this disease.

Although, there is no permanent cure available to treat Parkinson's disease.

Medication, along with other therapies such as exercise, can help relieve some of the symptoms of Parkinson's disease. Drugs such as the combination of levodopa therapy, dopamine agonists, cholinesterase inhibitors, and others are used to treat the various symptoms associated with the disease. Currently, combination therapy with levodopa is highly recommended as it is used to treat the motor symptoms of this disease. Even COMT inhibitors are gaining popularity with co-therapeutic agents for maximum effectiveness.In addition, various innovations in treatment methods, such as the development of neurostimulation tools, gene therapy, and neural transplantation procedures, act as other growth factors anticipated to impact the market positively. There are significant improvements in healthcare infrastructure coupled with extensive research and development (R&D) activities supported by governments and non-profit organizations to develop promising product portfolios.

However, the easy availability of alternative treatments and limited effectiveness of the treatment options slows down the growth of the Parkinson's disease treatment market in Latin America. Moreover, various side effects of the drugs may jeopardize market growth in the years to come. For example, impulsive and compulsive behaviors are possible side effects found with some medications. The expiration of the patent on key brand-name drugs will also limit the growth of the Latin American Parkinson's disease treatment market.

This research report on Latin American Parkinson’s disease treatment market has been segmented and sub-segmented into the following categories.

Latin America Parkinson’s Disease Treatment Market By Drug Class

• Dopamine Receptor Antagonists

  • Pramipexole

  • Ropinirole
  • Apomorphine
  • Rotigotine
• Mono Amine Oxidase Inhibitors
  • Selegiline
  • Rasagiline
• Carbidopa
• Anticholinergics
• Other Drug Classes

 Latin America Parkinson’s Disease Treatment Market By Distribution Channels

• Retailer Pharmacies
• Hospital Pharmacies
• Online Pharmacies

 Latin America Parkinson’s Disease Treatment Market By Patient Care Setting

• Clinics
• Hospitals 

 Latin America Parkinson’s Disease Treatment Market By Country

• Mexico
• Brazil
• Argentina
• Chile
• Peru
• Rest of Latin America

Geographically, Brazil accounted for the largest share of the Latin America Parkinson's disease treatment market in 2023, followed by Argentina with a substantial market share. Factors such as the high awareness among the elderly population increased research funding and grants, favorable government policies, a high prevalence of Parkinson's disease, will support the regional markets in these regions. According to the latest WHO data released, deaths from Parkinson's disease in Brazil reached 3,980, or 0.38% of all deaths, and a total of 240 incident PD cases have been identified. Meanwhile, the gross incidence was recorded at 31.24/100,000 people, with a prevalence of 395/100 000 in Mexico over 40 years old. Based on recent data, the male / female ratio was reported at 1.32 in the Mexican population.Other factors such as the rapidly growing geriatric population, promising clinical products, and favorable reimbursement policies are expected to drive the regional markets in Argentina, Mexico, Peru, and Columbia.

KEY MARKET PLAYERS

Some of the major players in the market are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).